CN113166056A - 一种雌激素受体下调剂的盐型、晶型及其制备方法 - Google Patents

一种雌激素受体下调剂的盐型、晶型及其制备方法 Download PDF

Info

Publication number
CN113166056A
CN113166056A CN201980078425.5A CN201980078425A CN113166056A CN 113166056 A CN113166056 A CN 113166056A CN 201980078425 A CN201980078425 A CN 201980078425A CN 113166056 A CN113166056 A CN 113166056A
Authority
CN
China
Prior art keywords
degrees
compound
formula
ray powder
powder diffraction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980078425.5A
Other languages
English (en)
Inventor
贺辉君
施沈一
陆剑宇
丁照中
胡利红
施斌
杨文谦
董加强
王铁林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Luoxin Biotechnology Shanghai Co ltd
Shandong Luoxin Pharmaceutical Group Co Ltd
Original Assignee
Luoxin Biotechnology Shanghai Co ltd
Shandong Luoxin Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Luoxin Biotechnology Shanghai Co ltd, Shandong Luoxin Pharmaceutical Group Co Ltd filed Critical Luoxin Biotechnology Shanghai Co ltd
Publication of CN113166056A publication Critical patent/CN113166056A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

一种雌激素受体下调剂的盐型、晶型及其制备方法被公开，所述盐型和晶型可治疗乳腺癌。

Description

PCT国内申请，说明书已公开。

Claims (24)

  1. PCT国内申请，权利要求书已公开。
CN201980078425.5A 2018-11-28 2019-10-17 一种雌激素受体下调剂的盐型、晶型及其制备方法 Pending CN113166056A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201811434915 2018-11-28
CN2018114349158 2018-11-28
PCT/CN2019/111624 WO2020108154A1 (zh) 2018-11-28 2019-10-17 一种雌激素受体下调剂的盐型、晶型及其制备方法

Publications (1)

Publication Number Publication Date
CN113166056A true CN113166056A (zh) 2021-07-23

Family

ID=70852402

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980078425.5A Pending CN113166056A (zh) 2018-11-28 2019-10-17 一种雌激素受体下调剂的盐型、晶型及其制备方法

Country Status (6)

Country Link
US (1) US20220017463A1 (zh)
EP (1) EP3889136A4 (zh)
JP (1) JP7416540B2 (zh)
KR (1) KR20210097742A (zh)
CN (1) CN113166056A (zh)
WO (1) WO2020108154A1 (zh)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103189361A (zh) * 2010-09-16 2013-07-03 亚拉冈制药公司 雌激素受体调节剂及其用途
CN106488767A (zh) * 2014-03-13 2017-03-08 豪夫迈·罗氏有限公司 调节雌激素受体突变体的方法和组合物
WO2017162206A1 (zh) * 2016-03-25 2017-09-28 南京明德新药研发股份有限公司 作为雌激素受体降解剂的吲哚并取代哌啶类化合物
WO2019057201A1 (zh) * 2017-09-25 2019-03-28 罗欣生物科技（上海）有限公司 一种雌激素受体抑制剂的晶型及其制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106660969A (zh) * 2014-08-11 2017-05-10 豪夫迈·罗氏有限公司 雌激素受体调节剂的结晶形式
BR122023025347A2 (pt) * 2015-06-12 2024-01-16 Gb006, Inc. Sal de meglumina ou trometamina de um composto, formas cristalinas e formulações farmacêuticas dos mesmos e seus usos
SI3519407T1 (sl) * 2016-09-30 2022-01-31 Receptos Llc Dimetilaminoetanolna sol modulatorja receptorja GLP-1

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103189361A (zh) * 2010-09-16 2013-07-03 亚拉冈制药公司 雌激素受体调节剂及其用途
CN106488767A (zh) * 2014-03-13 2017-03-08 豪夫迈·罗氏有限公司 调节雌激素受体突变体的方法和组合物
WO2017162206A1 (zh) * 2016-03-25 2017-09-28 南京明德新药研发股份有限公司 作为雌激素受体降解剂的吲哚并取代哌啶类化合物
WO2019057201A1 (zh) * 2017-09-25 2019-03-28 罗欣生物科技（上海）有限公司 一种雌激素受体抑制剂的晶型及其制备方法

Also Published As

Publication number Publication date
EP3889136A4 (en) 2022-08-24
JP2022510918A (ja) 2022-01-28
JP7416540B2 (ja) 2024-01-17
KR20210097742A (ko) 2021-08-09
EP3889136A1 (en) 2021-10-06
US20220017463A1 (en) 2022-01-20
WO2020108154A1 (zh) 2020-06-04

Similar Documents

Publication Publication Date Title
AU2014265279B2 (en) Bipyrazole derivatives as JAK inhibitors
RU2760266C2 (ru) Новые производные фенилпропионовой кислоты и их применение
AU2018251119B2 (en) Opioid receptor (MOR) agonist salt, fumarate salt I crystal form thereof and preparation method thereof
EP3983384B1 (en) N-(phenyl)-indole-3-sulfonamide derivatives and related compounds as gpr17 modulators for treating cns disorders such as multiple sclerosis
CN104302292A (zh) 表现出抗癌和抗增殖活性的吡啶酮酰胺以及类似物
WO2022116693A1 (zh) 一类glp-1r受体激动剂化合物及其用途
CN103153308B (zh) Trpa1受体拮抗剂
TW202220962A (zh) 選擇性NaV抑制劑的結晶形式及其製備方法
CN108727347A (zh) 一种阿片样物质受体(mor)激动剂的晶型及其制备方法
RU2722441C2 (ru) Замещённые индольные соединения в качестве понижающих регуляторов рецепторов эстрогена
WO2015113521A1 (zh) 氘代喹唑啉酮化合物以及包含该化合物的药物组合物
WO2023193563A1 (zh) 一种噻吩并吡啶化合物的晶型a、制备方法及其药物组合物
CN113166056A (zh) 一种雌激素受体下调剂的盐型、晶型及其制备方法
KR101424667B1 (ko) Ｎ1-고리아민-ｎ2-치환된 바이구아나이드 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 약학 조성물
US20220402936A1 (en) Crystalline form of a multi-tyrosine kinase inhibitor, method of preparation, and use thereof
TW202304864A (zh) 1,3-取代的環丁基衍生物及其用途
US11034653B2 (en) Crystal form of estrogen receptor inhibitor and preparation method therefor
TW201904954A (zh) 一種苯并哌啶類衍生物的鹽、其晶型及鹽、其晶型的製備方法
WO2022179624A1 (zh) 一种选择性NaV抑制剂的可药用盐、结晶形式及其制备方法
WO2021228236A1 (zh) 氘代四氢噻吩并[3,4-d]嘧啶二酮化合物以及包含该化合物的药物组合物
JP2024501202A (ja) 四置換オレフィン化合物の塩形、結晶及びその製造方法
WO2024042157A1 (en) Novel substituted quinoline and tetrahydronaphthalene carboxylic acid derivatives and therapeutic uses thereof
WO2024042163A1 (en) Novel substituted 2,3,4,9-tetrahydro-1h-pyrido[3,4-b]indole carboxylic acid derivatives, processes for their preparation and therapeutic uses thereof
WO2024042185A1 (en) Novel substituted tetrahydroisoquinoline-6- carboxylic acid derivatives, processes for their preparation and therapeutic uses thereof.
CN116903554A (zh) Vista和pd-1/pd-l1双靶点小分子抑制剂及其制备方法和用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination